Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Research & Development (2021 - 2025)

Prime Medicine (PRME) has disclosed Research & Development for 5 consecutive years, with $34.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 1.77% year-over-year to $34.7 million, compared with a TTM value of $160.6 million through Dec 2025, up 3.44%, and an annual FY2025 reading of $160.6 million, up 3.44% over the prior year.
  • Research & Development was $34.7 million for Q4 2025 at Prime Medicine, down from $44.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $44.0 million in Q3 2025 and bottomed at $100000.0 in Q3 2023.
  • Average Research & Development over 5 years is $31.3 million, with a median of $36.2 million recorded in 2024.
  • Peak annual rise in Research & Development hit 40240.0% in 2024, while the deepest fall reached 17.74% in 2024.
  • Year by year, Research & Development stood at $7.4 million in 2021, then skyrocketed by 292.72% to $29.1 million in 2022, then soared by 42.66% to $41.5 million in 2023, then fell by 17.74% to $34.1 million in 2024, then grew by 1.77% to $34.7 million in 2025.
  • Business Quant data shows Research & Development for PRME at $34.7 million in Q4 2025, $44.0 million in Q3 2025, and $41.4 million in Q2 2025.